Liu MH, Li YX, Liu Z. Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report. World J Clin Cases 2023; 11(5): 1115-1121 [PMID: 36874434 DOI: 10.12998/wjcc.v11.i5.1115]
Corresponding Author of This Article
Zhuo Liu, Doctor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. liuzhuo@firstosp-dmu.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 16, 2023; 11(5): 1115-1121 Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1115
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report
Mei-Hong Liu, Yan-Xia Li, Zhuo Liu
Mei-Hong Liu, Yan-Xia Li, Zhuo Liu, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
Author contributions: Liu MH and Liu Z reviewed the literature and contributed to the manuscript collection and interpretation of the clinical data and material; Li YX was responsible for the revision of the manuscript for important intellectual content; all authors contributed to the manuscript and approved the final version to be submitted.
Supported bythe Foundation of Science and Technology Bureau of Dalian, No. 2021JJ13SN70.
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: The authors have nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhuo Liu, Doctor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. liuzhuo@firstosp-dmu.com
Received: October 4, 2022 Peer-review started: October 4, 2022 First decision: December 19, 2022 Revised: January 8, 2023 Accepted: January 20, 2023 Article in press: January 20, 2023 Published online: February 16, 2023 Processing time: 112 Days and 22.7 Hours
Abstract
BACKGROUND
Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis. Currently, there are limited studies on C-SCLC, and there is no uniform standard treatment, especially for extensive C-SCLC, which still faces great challenges. In recent years, the development and progress of immunotherapy have provided more possibilities for the treatment of C-SCLC. We used immunotherapy combined with first-line chemotherapy to treat extensive-stage C-SCLC to explore its antitumor activity and safety.
CASE SUMMARY
We report a case of C-SCLC that presented early with adrenal, rib, and mediastinal lymph node metastases. The patient received carboplatin and etoposide with concurrent initiation of envafolimab. After 6 cycles of chemotherapy, the lung lesion was significantly reduced, and the comprehensive efficacy evaluation showed a partial response. No serious drug-related adverse events occurred during the treatment, and the drug regimen was well tolerated.
CONCLUSION
Envafolimab combined with carboplatin and etoposide in the treatment of extensive-stage C-SCLC has preliminary antitumor activity and good safety and tolerability.
Core Tip: Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer, which is relatively rare, aggressive, prone to early metastasis, and has a poor prognosis. With the development and progress of immunotherapy, several clinical studies have shown that programmed death ligand-1 combined with chemotherapy can effectively prolong the progression-free survival and median overall survival of patients with extensive stage small cell lung cancer, but its efficacy in C-SCLC is not exact. In this paper, we report a patient with extensive stage C-SCLC who was treated with envafolimab combined with carboplatin and etoposide with preliminary anti-tumor activity, safety and tolerability.
